Cargando…
The new in anticoagulation: factor XI inhibitors
Haemostasis and thrombosis are closely linked, so that any anticoagulant strategy available today that reduces the thrombotic risk inevitably increases the bleeding risk. However, epidemiological and experimental evidence suggests that inhibiting the contact pathway—the first phase of the intrinsic...
Autores principales: | Muscente, Francesca, De Caterina, Raffaele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120978/ https://www.ncbi.nlm.nih.gov/pubmed/37091652 http://dx.doi.org/10.1093/eurheartjsupp/suad070 |
Ejemplares similares
-
Pollution and coronary risk: how much does it matter?
por: Muscente, Francesca, et al.
Publicado: (2022) -
The temptation of anticoagulant therapy after transcatheter aortic valve implantation
por: Gatto, Laura, et al.
Publicado: (2023) -
Renal denervation and long-term results
por: Simonetti, Fiorenzo, et al.
Publicado: (2023) -
Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
por: Bisceglia, Irma, et al.
Publicado: (2023) -
Acute coronary syndromes: hospital management of dyslipidaemia with proprotein convertase subtilisin/kexin 9 inhibitors: time to act
por: Musumeci, Giuseppe, et al.
Publicado: (2023)